ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Boehringer Ingelheim will spend more than $62 million to build a facility for producing new active pharmaceutical ingredients at the company’s Biberach, Germany, site. The new facility will make clinical-scale quantities of compounds arising from the firm’s own drug development pipeline. The pilot plant facility will have 15 reactors with volumes from 100 to 300 L and four manufacturing bays, including four synthesis labs for scale-up work. Boehringer expects to complete construction of the plant and associated tech center in early 2014.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter